Financial Performance - In 2022, the company achieved a total revenue of CNY 195.13 million, with overseas sales accounting for 90.95% of total revenue, amounting to CNY 177.48 million[16]. - The company's operating revenue for 2022 was CNY 195,132,408.42, representing a year-on-year increase of 1.66% compared to CNY 191,946,299.04 in 2021[31]. - The net profit attributable to shareholders for 2022 was CNY 40,301,539.44, a significant increase of 76.13% from CNY 22,881,399.64 in 2021[31]. - The gross profit margin improved to 46.38% in 2022, up from 37.59% in 2021[31]. - Hearing aid revenue accounted for 91.65% of total revenue, with a year-on-year growth of 14.49% to 178.84 million yuan[46]. - The company reported a net profit growth rate of 80.39% in 2022 compared to a decline of 45.49% in 2021[35]. - The basic earnings per share for 2022 was CNY 0.82, reflecting a growth of 36.67% from CNY 0.60 in 2021[31]. - The cash flow from operating activities for 2022 was CNY 27,362,364.11, an increase of 8.47% from CNY 25,225,648.78 in 2021[34]. Research and Development - The company invested 15.61 million yuan in R&D, marking a 347.51% increase, with R&D expenses constituting 8.00% of total revenue[47]. - The company holds 140 patents and 8 copyrights, including 5 invention patents, demonstrating strong innovation capabilities[42]. - The company increased its R&D personnel from 45 to 62, with a higher proportion of employees engaged in R&D activities, rising from 14.24% to 16.40%[92]. - The company is actively developing digital hearing aids to align with market trends towards OTC, intelligent, professional, and personalized products[114]. - In 2022, the company's R&D investment reached a record high of 8.00% of total revenue, with plans to further increase R&D efforts in 2023, particularly for OTC hearing aids and HCP hearing aids[114]. Market Expansion and Sales - The company has established partnerships with major international retailers, including Walmart and Carrefour, enhancing its market presence[42]. - The company is focused on developing OTC hearing aids, which are expected to create new market opportunities and increase penetration rates[50]. - The company plans to enhance its overseas business development, particularly in the U.S. OTC market, following the easing of COVID-19 restrictions[111]. - The company plans to enhance market expansion efforts, focusing on increasing sales scale in both domestic and international markets, particularly in the Asia-Pacific, Europe, and the Middle East[113]. - The company has established three operational stores to enhance domestic sales and reduce reliance on overseas markets[120]. Corporate Governance and Compliance - The company is addressing risks related to governance and control by implementing internal control measures and enhancing its governance structure[117]. - The company has publicly disclosed that there are no false records or misleading statements in its financial reporting[143]. - The company has committed to eliminating all illegal occupation of funds and guarantees from the company and its subsidiaries[140]. - The company has established measures to address any potential economic losses resulting from breaches of competition commitments[145]. - The company will ensure effective management of raised funds, adhering to regulatory requirements and internal management systems[162]. Shareholder Commitments and Equity - The 2022 equity incentive plan granted a total of 675,000 restricted shares and 945,000 stock options to directors, senior management, and core employees[135]. - The company's share capital increased from 48.6 million shares to 49.275 million shares due to the implementation of the equity incentive plan[136]. - Major shareholders have pledged not to transfer or manage their shares for 12 months post-IPO, with a maximum of 25% of their shares allowed for transfer annually during their tenure[148]. - The company has committed to a profit distribution policy that prioritizes cash dividends, with a minimum of 10% of distributable profits to be distributed in cash annually, and a cumulative cash distribution of at least 30% of the average annual distributable profits over the last three years[169]. - The company will review its shareholder return plan at least every three years after listing on the selected tier, considering changes in circumstances or policies[171]. Investment and Asset Management - The company raised a total of RMB 210 million through a public offering, with a net amount of RMB 190.14 million after expenses[195]. - During the reporting period, the company used RMB 132.18 million of the raised funds, with a remaining balance of RMB 7.82 million as of December 31, 2022[197]. - The funds raised are allocated for the construction of a smart medical product production base and an intelligent hearing aid design research center[195]. - The total amount of raised funds invested to date is approximately ¥185.12 million, indicating a utilization rate of 95.62%[199]. - The company utilized part of the idle raised funds for cash management, with a total purchase amount of ¥12.5 million in structured deposits[199]. Social Responsibility - The company engaged in a series of successful public welfare activities in collaboration with Ruyi Tree in 2022[9]. - The company actively participated in social responsibility initiatives, providing free hearing health checks to 16,000 individuals and distributing 4,550 hearing aids in rural areas[106].

Financial Performance - The company achieved total operating revenue of CNY 195,132,408.42, representing a year-on-year increase of 1.66%[5] - Net profit attributable to shareholders reached CNY 40,295,863.91, a significant increase of 76.11% compared to the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 37,159,179.32, up 74.52% year-on-year[5] - Basic earnings per share increased to CNY 0.79, reflecting a growth of 31.67%[5] Assets and Equity - Total assets at the end of the reporting period were CNY 417,656,757.08, an increase of 11.19% year-on-year[5] - Shareholders' equity attributable to the company was CNY 365,890,374.70, up 9.62% from the previous year[5] Product Performance - Hearing aid products accounted for over 90% of total revenue, with a notable increase in the sales of high-margin digital hearing aids[5] Foreign Exchange Impact - The company benefited from foreign exchange gains due to the appreciation of the US dollar, which positively impacted profit margins[5] Future Plans - The company plans to continue increasing R&D investment to enhance product offerings and profitability[5] Cautionary Note - The financial data presented is preliminary and has not been audited, cautioning investors to be aware of potential risks[6]

Financial Performance - The net profit attributable to shareholders for 2022 is expected to be 40.30 million CNY, representing a 76.11% increase compared to 22.88 million CNY in the previous year[3] - The company experienced an increase in foreign exchange gains due to the appreciation of the US dollar, which positively impacted the gross profit margin and net profit[5] Revenue Composition - Hearing aid products accounted for over 90% of total revenue, with a significant increase in the sales of high-margin digital hearing aids contributing to the overall profit margin[4] Cautionary Notes - The financial data presented is preliminary and has not been audited, and investors are advised to exercise caution[6]

证券代码：872925 证券简称：锦好医疗 公告编号：2022-088 惠州市锦好医疗科技股份有限公司 关于接待机构投资者调研情况的公告 | --- | |------------------------------------------------------------------------| | | | 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 | | 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 | | 带法律责任。 | 惠州市锦好医疗科技股份有限公司（以下简称"公司"）于 2022 年 11 月 18 日接待了 71 家机构的调研，现将主要情况公告如下： 一、 调研情况 调研时间：2022 年 11 月 18 日 调研形式：网络调研 调研机构：申万宏源证券有限公司、国融基金管理有限公司、交银理财、上 海方物私募基金管理有限公司、浙商证券股份有限公司（自营）、上海觉承资产 管理有限公司、嘉合基金管理有限公司、兴证资产管理有限公司、太平资产管理 有限公司、南京证券股份有限公司、中国人寿养老保险等 上市公司接待人员：董事会秘书 段皓龄先生 二、 调 ...

证券代码：872925 证券简称：锦好医疗 公告编号：2022-011 惠州市锦好医疗科技股份有限公司 关于接待机构投资者调研情况的公告 | --- | |------------------------------------------------------------------------| | | | 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 | | 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 | | 带法律责任。 | 惠州市锦好医疗科技股份有限公司（以下简称"公司"）于 2022 年 1 月 19 日接待了 7 家机构的调研，现将主要情况公告如下： 一、 调研情况 调研时间：2022 年 1 月 19 日 调研形式：网络调研 调研机构：中泰证券股份有限公司、上海纯达资产管理有限公司、山西证券 有限责任公司、长城基金管理有限公司、凯石基金管理有限公司、上银基金管理 有限公司、上海尚雅投资管理有限公司 上市公司接待人员：董事会秘书段皓龄先生 二、 调研的主要问题及公司回复概要 问题 1：助听器是否会受到国家集采等相关政策的影响？助听器的验配是以 ...

证券代码：872925 证券简称：锦好医疗 公告编号：2022-057 惠州市锦好医疗科技股份有限公司 关于接待机构投资者调研情况的公告 | --- | |------------------------------------------------------------------------| | | | 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 | | 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 | | 带法律责任。 | 惠州市锦好医疗科技股份有限公司（以下简称"公司"）于 2022 年 7 月 21 日接待了 2 家机构的调研，现将主要情况公告如下： 一、 调研情况 调研时间：2022 年 7 月 21 日 调研地点：公司会议室 调研形式：现场调研 调研机构：上海申银万国证券研究所有限公司、上海鑫疆投资管理有限公司 上市公司接待人员：董事会秘书 段皓龄先生 二、 调研的主要问题及公司回复概要 问题 1、公司第二季度整体的经营情况如何？ 回答：公司第二季度依旧延续去年的经营战略，以调整产品结构为主，一方 面减少毛利率较低的雾化器产品，另一方面继 ...

Revenue and Profitability - The company's total revenue for the reporting period (January 1, 2022, to June 30, 2022) was CNY 92.21 million, with overseas sales accounting for 87.21% of total revenue, amounting to CNY 80.42 million[14]. - The company's operating revenue for the current period is ¥92,205,975.82, a decrease of 7.54% compared to the previous year[27]. - The net profit attributable to shareholders increased by 86.20% to ¥20,539,424.47, compared to ¥11,030,554.78 in the same period last year[27]. - The gross profit margin improved to 45.26%, up from 36.47% in the previous year[27]. - The revenue from hearing aids was ¥87,271,582.13, with a gross margin of 45.99%, reflecting a year-on-year increase of 8.73%[52]. - The company achieved operating revenue of 92.21 million yuan, a year-on-year decrease of 7.54%, while net profit attributable to shareholders increased by 86.20% to 20.54 million yuan[36]. Assets and Liabilities - The company’s total assets increased by 2.10% to ¥383,518,724.26, while total liabilities decreased by 5.87% to ¥40,121,757.63[28]. - As of June 30, 2022, total assets amounted to 383.52 million yuan, with net assets attributable to shareholders at 344.69 million yuan, reflecting growth of 2.10% and 3.26% respectively compared to the beginning of the period[36]. - The total assets increased from ¥375,622,625.19 to ¥383,518,724.26, a growth of about 2.4%[151]. - Current liabilities decreased from ¥40,438,314.48 to ¥30,581,390.58, a reduction of approximately 24%[151]. Cash Flow - The net cash flow from operating activities was ¥7,468,514.74, a significant recovery from a negative cash flow of ¥17,817,167.16 in the previous year[29]. - The net cash flow from operating activities for the first half of 2022 was ¥7,468,514.74, a significant improvement compared to a net outflow of ¥17,817,167.16 in the same period of 2021[165]. - Cash inflow from investment activities surged to ¥281,981,430.61, a substantial increase from ¥30,524,052.06 in the first half of 2021[166]. - The total cash and cash equivalents at the end of the period stood at ¥67,658,365.54, down from ¥71,640,283.15 at the beginning of the period[166]. Research and Development - The company invested ¥6,651,300 in R&D, an increase of 22.59% year-on-year, and obtained 10 new patent authorizations during the reporting period[35]. - Research and development expenses increased to CNY 6,651,300.70 in the first half of 2022, compared to CNY 5,425,756.80 in the same period of 2021, reflecting a growth of 22.6%[159]. - The company has reported significant research and development expenditures, reflecting its commitment to innovation and future growth[182]. Market Presence and Expansion - The company is actively expanding its market presence through participation in various domestic and international exhibitions to acquire new customers and orders[14]. - The company has established two specialized stores in the domestic market to enhance brand promotion and market presence[35]. - The company plans to enhance brand recognition and domestic sales through e-commerce platforms and self-operated stores[71]. - The company is increasing its investment in domestic operations and aims to balance its domestic and overseas sales, reducing reliance on foreign markets[71]. Corporate Governance and Compliance - The company has established a modern corporate governance structure, but there are risks associated with the actual controllers' influence over major decisions[13]. - The company is currently fulfilling its commitment to avoid any illegal occupation of funds and assets, as well as external guarantees[83]. - The company has committed to strictly adhere to regulations regarding the lock-up and reduction of shares, which is currently being fulfilled[84]. - The company is actively working on reducing related party transactions and is in compliance with this commitment[83]. Shareholder and Equity Information - The company distributed a cash dividend of CNY 2.00 per 10 shares on June 1, 2022[131]. - The total number of unrestricted shares increased from 14,792,635 to 16,966,635, representing a rise from 30.44% to 34.43% of total shares[113]. - The total share capital increased from 48,600,000 to 49,275,000 shares due to the implementation of the 2022 equity incentive plan, which involved the issuance of 675,000 restricted shares[115]. - The company has a three-year dividend return plan for shareholders following the public issuance of shares[85]. Risks and Challenges - The company faces risks related to foreign exchange fluctuations, as its products are primarily priced in USD, impacting revenue when converted to CNY[14]. - The company is facing risks from geopolitical conflicts and trade tensions that may affect its overseas sales and overall performance[71]. - The company has implemented foreign exchange hedging tools to mitigate the impact of currency fluctuations on its performance[72]. Other Financial Information - The company reported a financial expense of CNY -1,441,503.31 in the first half of 2022, compared to CNY 821,561.29 in the same period of 2021, indicating a positive shift in financial management[159]. - The company recognized 54 core employees, with the latest count at 53 after one resignation[145]. - The company has not made any changes to accounting policies or estimates compared to the previous year, ensuring consistency in financial reporting[182].

Financial Performance - Net profit attributable to shareholders for the first quarter of 2022 was CNY 5,586,935.69, a decrease of 10.83% compared to CNY 6,265,365.91 in the same period last year[15] - Operating revenue for the first quarter of 2022 was CNY 37,694,584.15, down 1.42% from CNY 38,237,391.48 year-on-year[15] - Basic earnings per share decreased by 32.38% to CNY 0.11 from CNY 0.17 in the same period last year[15] - The company's net cash flow from operating activities for the first quarter was CNY 7,272,807.75, a decline of 3.42% compared to CNY 7,530,507.15 in the previous year[15] - Comprehensive income for Q1 2022 totaled 5,365,879.18, compared to 6,080,797.96 in Q1 2021, reflecting a decrease of about 11.8%[50] - Operating profit for Q1 2022 was 5,706,635.43, compared to 6,807,626.86 in Q1 2021, showing a decline of around 16.2%[46] - Total operating revenue for Q1 2022 was 37,674,137.74, a decrease from 38,237,391.48 in Q1 2021, representing a decline of approximately 1.5%[48] - Net profit for Q1 2022 was 5,365,879.18, down from 6,080,797.96 in Q1 2021, indicating a decrease of about 11.8%[46] Assets and Liabilities - Total assets as of March 31, 2022, amounted to CNY 379,752,076.69, reflecting a 1.10% increase from CNY 375,622,625.19 at the end of the previous year[15] - The company's total liabilities to assets ratio was 10.90% as of March 31, 2022, down from 11.35% at the end of the previous year[15] - The net assets attributable to shareholders increased to CNY 339,377,445.23, representing a 1.67% increase from CNY 333,790,509.54 at the end of the previous year[15] - Current liabilities decreased to CNY 39,239,452.20 from CNY 40,438,314.48, a reduction of approximately 2.96%[38] - Total liabilities decreased to CNY 41,389,558.88 from CNY 42,625,986.56, indicating a decline of about 2.91%[39] - Shareholders' equity increased to CNY 338,362,517.81 from CNY 332,996,638.63, showing a growth of approximately 1.10%[39] Cash Flow - Cash and cash equivalents decreased from ¥71,640,283.15 on December 31, 2021, to ¥41,570,848.36 on March 31, 2022, representing a decline of approximately 42%[37] - Operating cash inflow for Q1 2022 was CNY 46,223,409.90, a decrease of 21.0% from CNY 58,626,742.69 in Q1 2021[51] - Cash inflow from operating activities for the parent company in Q1 2022 was CNY 46,170,386.26, down from CNY 58,627,113.60 in Q1 2021[54] - The parent company's net cash flow from operating activities in Q1 2022 was CNY 6,765,897.00, a decrease from CNY 8,011,473.90 in Q1 2021[54] - Cash outflow for purchasing goods and services in Q1 2022 was CNY 24,862,533.50, down 30.2% from CNY 35,537,659.34 in Q1 2021[51] Shareholder Information - The number of ordinary shareholders as of the report date was 8,513[21] - The major shareholders include Wang Min with 26.07% and Wang Fang with 19.53% of the total shares[24] - The total shares held by the top ten shareholders amount to 37,256,377, representing 76.67% of the total shares[24] Commitments and Compliance - The company has committed to avoiding related party transactions and ensuring compliance with regulations[29] - The company has confirmed that all previously disclosed commitments are being fulfilled[29] - The company committed to avoiding all illegal occupation of funds and guarantees by the company and its subsidiaries[30] - The company has also committed to publicly disclosing information and ensuring there are no false records or misleading statements as of October 30, 2020[33] Investments and Expenses - Research and development expenses increased to 3,042,481.56 in Q1 2022 from 2,376,842.25 in Q1 2021, reflecting a growth of approximately 27.9%[46] - Long-term equity investments rose to CNY 9,637,742.33 from CNY 5,600,000.00, an increase of approximately 72.80%[42] - Investment income for Q1 2022 was 158,080.00, down from 485,846.58 in Q1 2021, indicating a decline of about 67.5%[46] Other Financial Metrics - The total non-recurring gains and losses for the first quarter amounted to CNY 378,919.17 after tax[19] - Financial expenses decreased to 392,582.84 in Q1 2022 from 492,377.92 in Q1 2021, a reduction of approximately 20.2%[46] - The company reported a credit impairment loss of 122,066.95 in Q1 2022, significantly lower than 637,683.86 in Q1 2021, a decrease of approximately 80.9%[46]

Financial Performance - The total operating revenue for the reporting period was CNY 191.95 million, with overseas revenue accounting for CNY 165.45 million, representing 86.19% of total sales[17]. - The company's operating revenue for 2021 was ¥191,946,299.04, a decrease of 9.24% compared to ¥211,480,597.53 in 2020[29]. - The net profit attributable to shareholders for 2021 was ¥22,881,399.64, down 44.72% from ¥41,388,470.16 in 2020[29]. - The company's net profit growth rate for 2021 was -45.49%, compared to a growth rate of 65.08% in 2020[34]. - The company achieved operating revenue of CNY 191.95 million, a decrease of 9.24% year-on-year[49]. - The net profit attributable to shareholders was CNY 22.88 million, a decrease of 44.72% year-on-year, impacted by exchange rate fluctuations and rising raw material costs[49]. - The gross profit margin decreased to 37.59% from 41.85% in the previous year, indicating pressure on profitability[60]. - The company's total revenue for the reporting period was 191,946,299.04 yuan, a decrease of 9.24% compared to the same period last year[71]. - The revenue from nebulizers was 22,866,022.76 yuan, down 50.13% year-on-year, primarily due to rising raw material prices affecting profit margins[71]. - The cash flow from operating activities for 2021 was ¥25,225,648.78, a decrease of 43.37% from ¥44,544,867.68 in 2020[32]. Research and Development - The company invested CNY 12.14 million in R&D, an increase of 13.79% year-on-year, and CNY 24.76 million in sales expenses, an increase of 22.40% year-on-year[49]. - The company has focused on R&D projects such as DSP digital chips and self-developed hearing test algorithms, with the DSP digital chip now in mass production[98]. - The company plans to continue investing in R&D, focusing on AI algorithms for the next generation of hearing aids to maintain its competitive edge[98]. - Research and development (R&D) expenditure for the current period was ¥12,136,110.72, representing 6.32% of operating revenue, an increase from 5.04% in the previous period[94]. - The proportion of R&D personnel in the total workforce was 14.83% at the end of the period, slightly up from 14.24% at the beginning[95]. Market Expansion and Strategy - The company is actively expanding its market presence through participation in various domestic and international exhibitions[16]. - The company aims to expand its market presence in North America and Europe, leveraging the recovery post-COVID-19 and the launch of the OTC market[107]. - The company plans to develop digital hearing aids, focusing on OTC, intelligent, and personalized trends to better meet market demands[108]. - The company targets to increase its revenue from BTC business and promote its own brand in the domestic market[110]. - The company plans to reduce reliance on overseas markets by increasing domestic sales efforts and expanding sales channels[118]. Corporate Governance and Compliance - The company has established a modern corporate governance structure, which is crucial for its continued growth and compliance with regulatory requirements[15]. - The company is currently fulfilling its commitment to avoid any illegal occupation of funds, assets, and external guarantees[130]. - The company has committed to strictly adhere to regulations regarding the lock-up and reduction of shares, ensuring compliance with relevant requirements[130]. - The company has publicly disclosed that there are no false records or misleading statements in its information submissions[133]. - The company has committed to ensuring that the public offering documents do not contain false records, misleading statements, or significant omissions, and will repurchase all newly issued shares if such issues are identified[170]. Risks and Challenges - The company has faced challenges due to the global pandemic, impacting new order acquisition and overall sales performance[16]. - The company has identified several major risks, including potential changes in export tax policies and the impact of external market conditions on sales[15]. - The company faces uncertainties due to the ongoing global pandemic, rising raw material prices, and exchange rate fluctuations[113]. - The company faces risks from exchange rate fluctuations due to its high overseas sales, which may impact financial performance[119]. - The company has implemented measures such as foreign exchange hedging to mitigate exchange rate risks[119]. Shareholder Commitments and Stock Management - The company issued a total of 1,250,000 shares in 2021, increasing the total share capital to 48,600,000 shares[26]. - The company will repurchase shares to stabilize stock prices, with the repurchase amount not exceeding 20% of the previous year's audited net profit attributable to shareholders[142]. - The controlling shareholder will increase their holdings if the stock price stabilization measures are triggered, with a minimum investment of 20% of the previous year's cash dividends[140]. - The company has committed to a profit distribution policy that ensures cash dividends will not exceed 10% of the distributable profits for the year, with a cumulative cash distribution of at least 30% of the average annual distributable profits over the last three years[162]. - The company will prioritize cash dividends when conditions allow, ensuring a stable and continuous return to investors[161].